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ABSTRACT 
Objective: Carbamazepine is typically used for the treatment of seizure disorders and neuropathic pain. One of the major problems with this drug is 
its low solubility in water; therefore the objective of this study was to enhance the solubility of carbamazepine by complexation with cyclodextrin to 
be formulated as effervescent and dispersible granules. 
Methods: Solvent evaporation method was used to prepare, binary (Carbamazepine/β-cyclodextrin) complex and ternary (Carbamazepine/β-
cyclodextrin/hydroxypropyl methyl cellulose (HPMC E5). The more soluble complex will be further formulated as unit dose effervescent and 
dispersible granules. The complexes were evaluated for their solubility, drug content, percentage practical yield and differential scanning 
calorimetery (DSC) to confirm the formation of the complex.  
Results: The ratio of effervescent components, amount of effervescent base, amount of croscarmellose sodium (superdisintegrant) within the 
formula were found to play a role in the percentage of drug dissolved. Among the all prepared formulas, the effervescent granules containing 
ternary complex equivalent to 200 or 100 carbamazepine with effervescent base of 1:2:3.4 citric acid: tartaric acid: sodium bicarbonate not less 
than 48% w/w and 3% w/w croscarmellose sodium within the formula may be considered as a promising formulas regarding the amount of drug 
dissolved within 5 min.  
Conclusion: The solubility of carbamazepine was enhanced by complexation with β-cyclodextrin and HPMC E5 as a ternary complex. Hence 
effervescent and dispersible granules of carbamazepine with good flow properties can be successfully prepared by using this complex. 
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Granules including effervescent granules are popular delivery 
systems for many pharmaceutical products. They provide a highly 
palatable formula which can avoid bitter taste of drugs with ease of 
administration to patients for quick relief. They are a convenient 
form to dispense drugs with a large dose [1, 2]. 
Addition of effervescent granules into a glass of water just before the 
administration will be quickly dispersed or dissolved by the 
liberation of carbon dioxide in water due to an interaction between 
acid with alkali metal carbonates or bicarbonate. The dissolution of 
the drug in water,as well as taste masking, is enhanced due to 
liberation in carbon dioxide gas [3]. 
Carbamazepine is very slightly soluble in water [4], it is an 
antiepileptic drug, and it is also considered to be one of the most 
vital drugs for the relief of pain associated with trigeminal neuralgia, 
it shows erratic dissolution profile in gastric and intestinal fluid and 
its absorption is fairly complete after single oral doses due to its 
poor water solubility [5]. 
Cyclodextrins are capable of forming inclusion complexes with a 
wide variety of hydrophobic molecules by taking up a whole 
molecule, or some part of it, into the cavity. Thus it improves 
pharmaceutical properties like solubility, dissolution rate and 
stability. These complexes also act as penetration enhancers by 
increasing the availability of the drug at the surface of a biological 
membrane and even palatability without affecting their intrinsic 
lipophilicity or pharmacological properties [6]. 
The main aim of this work was to enhance patient compliance by the 
formulation of carbamazepine as unit dose effervescent granules to 
be easily taken by children and elderly patients. This requires 
improving the poor water solubility of carbamazepine, by preparing 
it as a soluble complex with β-cyclodextrin. 
MATERIALS AND METHODS 
Carbamazepine, β-cyclodextrin and croscarmellose sodium 
(Hyperchem, China), hydroxypropyl methyl cellulose (HPMC E5) 
and polyvinylpyrrolidone (PVP) (Himedica, India), citric acid 
(Panreac, Barcelona Espain), tartaric acid (Fischer, China), sodium 
bicarbonate (Furat Drug Industry, Iraq), mannitol (Sigma, Aldrich, 
Germany), aspartame (Gerhard, Buchmann KG, Germany) all other 
ingredients are of analytical grade. 
Methods 
Determination of carbamazepine saturated solubility in water 
The solubility of carbamazepine was determined in water using the 
shake–flask method at 25 °C. An excess amount of carbamazepine 
pure powder was taken and dissolved in water (10 ml) with 
continuous shaking in the water bath (Copley scientific, U. K) for 48 
h at 25 °C±2 °C. Then sample was taken, filtered by using millipore 
filter paper 0.45 μm, and the filtrate was diluted suitably and 
analyzed spectrophotometrically (Specord, Japan spectro-
photometer)at 284 nm to determine the dissolved quantity of 
carbamazepine [7] 
Preparation of carbamazepine-β-cyclodextrin complex 
Two steps were required to prepare carbamazepine-β-cyclodextrin 
complex:- 
First-phase solubility studies  
Phase solubility studies for both binary (carbamazepine and β-
cyclodextrin) and ternary systems (carbamazepine, β-cyclodextrin 
and HPMC E5) were carried out according to the method reported 
by Higuchi and Connors [8] Excess amount of drug was added to 10 
ml vials containing aqueous solutions of increasing concentrations 
of β-cyclodextrin (0.001M to 0.01M) and shaken at 25±0.5 °C. 
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Experiment for the ternary system was performed analogously to 
those for the binary systems, but in the presence of 0.25% w/v 
HPMC E5[9] After 48 h mixing, the samples were filtered through a 
millipore filter paper 0.45 μm., the concentration of the dissolved 
carbamazepine was determined spectrophotometrically at 284 nm. 
Phase solubility curve was obtained by plotting the molar 
concentration of the dissolved carbamazepine versus the molar 
concentration of β-cyclodextrin. The molar ratio of drug to β-
cyclodextrin required for best complex formation and the degree of 
their association (Ka) is to be determined from the values of slopes 
and the intercepts (So) of the lines obtained from this curve. 





Where so is the intrinsic solubility of the drug 
Second-solvent evaporation method for preparation of the 
complex 
For the preparation of carbamazepine-β-cyclodextrin complex, the 
aqueous solution of a required amount of β-cyclodextrin was added to a 
methanolic solution of carbamazepine. The resulting mixture was stirred 
for 1 hour and evaporated at a temperature of 45 °C until dried. The 
dried mass was pulverized and sieved through sieve no.20 [10] 
The ternary complex comprising of 0.25% w/v (HPMC E5) was 
prepared by first dissolving required amounts of β-cyclodextrin and 
polymer in distilled water which was then added to the methanolic 
solution of carbamazepine [9]and then the same procedure was 
done like that for the binary system. 
Physical mixture 
A quantity equivalent to 1 mole of carbamazepine and 1 mole of β-
cyclodextrin were mixed in a mortar for about one hour with 
constant trituration, passed through sieve no. 20 and stored in a 
desiccator [11]. 
Characterization of the complex 
Solubility 
The solubility of the complexes was determined by shake flask 
method as mentioned previously. The results were compared with 
those of pure drug and physical mixture of drug and β-cyclodextrin. 
Percent practical yield  
Percentage practical yield was calculated to know about the efficiency of 
the method. Inclusion complex was collected and weighed to determine 
practical yield from the following equation [12] 
Practical yield (%) = 
Practical mass
Theoretical mass (Drugβcyclodextrin)
 x 100 
Determination of drug content  
Drug content was determined by taking 5 mg of complex and 
transferred to 50 ml volumetric flask and volume was made up to 
the mark with distilled water. From this 1 ml was taken in 10 ml 
volumetric flask and the volume was adjusted up to the mark with 
methanol. The absorbance of the solution was measured 
spectrophotometrically at 285 nm [13] 
Differential scanning calorimetry (DSC) 
The DSC curves were obtained in a Shimadzu, Japan DSC using 
aluminum pan with about 2 mg of samples (pure drug, β-cyclodextrin, 
HPMC E5, physical mixture of drug and β-cyclodextrin, binary and 
ternary complexes), under dynamic N2 atmosphere and heating rate of 
10 °C min−1 under a temperature range 25 °C-400 °C [14] 
Preparation of granules by wet granulation  
For preparation of effervescent granules by wet granulation method; 
an amount of complex (binary or ternary) equivalent to 200 mg or 
100 mg of carbamazepine was mixed with a certain quantity of 
effervescent base, Croscarmellose sodium as a superdisintegrant to 
promote the bursting effect of the granules [15], aspartame as 
sweetener and mannitol was added as a diluent to make 5 gram of 
powder as a sachet dosage form. Sufficient amount of 2% alcoholic 
solution of polyvinylpyrrolidone (PVP) as a binder was added to 
make a damp mass. This mass was passed through sieve no 20 to get 
granules which were dried in hot air oven at 40 °C [16] 
Carbamazepine dispersible granules were prepared in the same way 
but without the presence of the effervescent base 
Evaluation of granules 
In vitro effervescence time 
One dose of effervescent or dispersible granules (5 g.) equivalent to 
200 or 100 mg of carbamazepine was added in 200 ml of distilled 
water and the time for in vitro effervescence till it ceased or that for 
complete disintegration of dispersible granules was determined [17] 
pH of solution 
One dose of (100 or 200) mg granules was added to (200 ml) 
distilled water. After complete dissolution, the solution pH was 
measured by a pH meter (Hanna, Italy) [18] 
In vitro drug release 
One dose of the effervescent granules was accurately weighed and 
added to 200 ml of distilled water in an appropriate beaker. After 5 
min [4], filtration was done with a millipore filter paper 0.45 μm. 
The filtrate was diluted with water, and the quantity of the released 
carbamazepine was determined spectrophotometrically at 284 nm 
Determination of flow properties 
The flow properties were determined only for those formulas which 
release an acceptable amount of drug to give us further 
conformation about ease of packaging of these granules by the 
manufacturer and the ease of handling by the patient. 
The flow property can be determined by measuring the angle of 
repose, bulk and tapped density, Hausner’s ratio and compressibility 
index [1]. The results were compared with the pure powder. 
Angle of repose 
The angle of repose is a relatively simple technique for estimating 
the flow properties of a powder. It can easily be determined by 
allowing powder to flow through a funnel, and fall freely onto a 
surface. The height and diameter of the resulting cone are measured 
and the angle of repose is calculated from this equation  




Where h is the height of the powder cone and r is the radius of the 
powder cone 
Bulk density 
It is the ratio of the total mass of powder to the bulk volume of 
powder. It was measured by pouring a weighted mass of powder 
into a measuring cylinder, and the initial volume was noted. This 
initial volume was called the bulk volume. The bulk density was 
calculated according to the equation mentioned below and it was 





Tapped density  
It is the ratio of total mass of the powder to the tapped volume of the 
powder. It was measured by pouring a weighted mass of powder into a 
measuring cylinder. Tapped volume was measured by tapping the 
powder until no further change in the powder volume was observed. 
Tapped density was expressed in g./cm3 and was given by this equation:  




Compressibility index (Carr’s index)  
Compressibility is the ability of the powder to decrease in volume 
under pressure using bulk density and tapped density. The 
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percentage compressibility of powder was determined, which was 
given as Carr’s index (%). It was indirectly related to the relative 
flow rate. 
Carr’s index = 
Tapped deensityBulk densiy
Tapped density
 x 100 
Hausner’s ratio 
Hausner’s ratio was determined by the following equation  




Factors affecting the physical properties of effervescent 
granules 
Effect of effervescent components  
The effects of citric acid and tartaric acid on effervescence time and pH 
and amount of drug released were investigated by changing the ratio of 
citric acid: tartaric acid: sodium bicarbonate as follows: 1: 2: 3.4 (for F1 
and F3) and doubling the amount of citric acid for (F2 and F4) keeping 
the total concentration of the effervescent base within the formula 
constant that is equal to 60% w/w as shown in table 1 
 
Table 1: Composition of effervescent granules of carbamazepine/β-cyclodextrin complex 
Ingredient (mg) F1 F2 F3 F4 
Complex equivalent to 200 mg carbamazepine 1222 1222 1222 1222 
Citric acid 468.75 810.8 468.75 810.8 
Tartaric acid 937.5 810.8 937.5 810.8 
Sodium bicarbonate 1593.75 1378.4 1593.75 1378.4 
Croscarmellose sodium 150 150 75 75 
PVP 2%Alcoholic solution Q. S  Q. S  Q. S  Q. S 
Aspartame 5 5 5 5 
Mannitol up to 5000 5000 5000 5000 
 
Effect of the concentration of effervescent base 
The effect of concentration of effervescent base on the physical 
properties of effervescent granules prepared from ternary 
complex was studied by using 36% w/w for F5, 48% w/w for F6, 
and 60% w/w for F7 and F9 keeping the ratio of citric acid: 
tartaric acid: sodium bicarbonate as 1: 2: 3.4. While F8 ٭and F10٭ 
represented dispersible granule free from the effervescent base. 
The compositions of all these formulas are shown in tables 2A and 
2B. 
 
Table 2A: Composition of effervescent and dispersible granules of carbamazepine/β-Cyclodextrin/HPMC E5 complex equivalent to 200 
mg carbamazepine 
Ingredient (mg) F5 F6 F7 F8٭ 
Complex equivalent to 200 mg carbamazepine 1372.3 1372.3 1372.3 1372.3 
Citric acid 281.25 375 468.75 0 
Tartaric acid 562.5 750 937.5 0 
Sodium bicarbonate 956.25 1275 1593.75 0 
Croscarmellose sodium 150 150 150 150 
PVP 2% Alcoholic solution Q. S.  Q. S.   Q. S.  Q. S. 
Aspartame 5 5 5 5 
Mannitol up to 5000 5000 5000 5000 
F 8٭ Dispersible granules formula 
 
Table 2B: Composition of effervescent and dispersible granules of carbamazepine/β-cyclodextrin/HPMC E5 complex equivalent to 100 
mg carbamazepine 
Ingredients (mg) F9 F10٭ 
Complex equivalent to 100 mg carbamazepine 686.15 686.15 
Citric acid 468.75 0 
Tartaric acid 937.5 0 
Sodium bicarbonate 1593.75 0 
Croscarmellose sodium 150 150 
PVP 2% Alcoholic solution Q. S.  Q. S. 
Aspartame 5 5 
Mannitol up to 5000  5000 
 F 10 *Dispersible granules formula  
 
Effect of concentration of superdisintegrant 
To study the effect of concentration of superdisintegrant, F1and F2 
which composed of 3%w/w croscarmellose sodium were prepared 
(table 1) and the physical properties of the resultant granules were 
compared with those in F3 and F4 which composed of 1.5% 
croscarmellose sodium 
Statistical analysis  
Using Microsoft Excel 2010, the results of the experiments are given 
as a mean sample (of three results)±standard deviation (SD).  
RESULTS AND DISCUSSION 
Determination of saturated solubility in water  
The saturated solubility of carbamazepine in water was found to be 
equal to 173.3 mcg/ml or 173.3 mg/l, which is nearly the same as 
the reported value (170 mg/l) This indicated that the drug is very 
slightly soluble in water [19] 
Preparation of carbamazepine complex  
Phase solubility studies 
No changes in λ max of the drug were found after complexation 
with β-cyclodextrin. Hence the concentration of the dissolved 
carbamazepine was determined spectrophotometrically at 284 
nm which is the λ max of the drug in water. The phase solubility 
curve (fig. 1) showed that there is a linear increase in the 
solubility of the drug with the increase in the molar 
concentration of β-cyclodextrin alone or in the presence of 
HPMC E5. The further increase in the solubility of the drug in the 
presence of HPMC E5 in comparison to that of β-cyclodextrin 
alone can be explained to be as a result of the synergistic effect 
between these components [20] 
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Fig. 1: Phase solubility study of carbamazepine/β-cyclodextrin and carbamazepine/β-cyclodextrin/HPMC E5 complexes 
 
Since the slope of the lines in both cases was less than 1, so the 
drug formed a complex with β-cyclodextrin in a molar ratio of 
1:1[8]. Therefore, this ratio was used for the preparation of 
complexes. Also the association constant (Ka) for 
carbamazepine/β-cyclodextrin was equal to 684.38 M−1 while the 
(Ka) for carbamazepine/β-cyclodextrin/HPMC E5 was equal to 
2636.31 M-1 which indicate that HPMC E5 enhance complexation 
of carbamazepine in the ternary system [20]. Both values were 
within the accepted range value of the association constant is 
between 50 and 5000M−1 [21] 
Characterization of the complex  
Physical properties 
The physical properties of the prepared carbamazepine complexes in 
comparison with those of pure drug and the physical mixture of drug 
and β-cyclodextrin are summarized in table 3. The results indicated that 
the solubility of the drug increased due to the presence of β-cyclodextrin 
(physical mixture) and formation of an inclusion complex with or 
without HPMC E5 which enhanced the wettability of particles, resulting 
in increased the solubility of the drug [20] 
 
Table 3: The physical properties of the prepared carbamazepine complexes, pure drug and the physical mixture of drug and β-
cyclodextrin 
Component Solubility* Percent Yield Drug content 
Carbamazepine 173.3 mcg/ml±0.36 ----- ----- 
Physical mixture 1.46 mg/ml±0.035 100% 100% 
Carbamazepine/β-cyclodextrin complex 2.04 mg/ml±0.106 94.8%  100% 
Carbamazepine/β-cyclodextrin/HPMC E5 complex 4.024 mg/ml±±0.107 93.2% 100% 
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Fig. 2: DSC thermogram of (A) Carbamazepine, (B) β-Cyclodextrin, (C) HPMC E5, (D) Physical mixture, (E) β-cyclodextrin/Carbamazepine 
complex and (F) β-Cyclodextrin/Carbamazepine/HPMC E5 complex 
 
Differential scanning calorimetry (DSC) 
The DSC thermograms of carbamazepine, β-cyclodextrin, HPMC E5, 
physical mixture of carbamazepine/β-cyclodextrin and 
carbamazepine/β-cyclodextrin/HPMC E5 complex are illustrated in 
(fig. 2A-F). The pure drug showed a sharp endothermic peak at 193 
°C corresponding to its melting point. Thermogram of the β-
cyclodextrin showed a broad peak at 110.03 °C which is attributed 
to dehydration of water molecules present in β-cyclodextrin cavity 
while the peak at 309.92 °C corresponds to its melting point, while, 
HPMC E5 showed no sharp endothermic peaks indicting no exact 
melting points [20]. 
Physical mixture of system showed characteristic peaks for both the 
drug and the peaks β-cyclodextrin with slight decrease in their 
intensity due to dilution effect while, in carbamazepine/β-
cyclodextrin complex there was a small endothermic peak at 174.2 
°C, which is attributed to the presence of a small amount of 
polymorphic form of carbamazepine [19] and a decrease in the 
intensity of the characteristic endothermic peak of carbamazepine at 
188.41 °C. In addition, the intensity of this peak was further 
decreased in carbamazepine/β-cyclodextrin/HPMC E5 complex 
suggests that the complexation efficiency was enhanced due to the 
presence of this polymer leading to a decrease in the amount of free 
drug in the ternary complex as compared to physical mixture [20]. 
Preparation of granules 
Factors affecting the physical properties of effervescent 
granules 
Effect of effervescent components 
Formulas F1 and F3 with a ratio of citric acid: tartaric acid: sodium 
bicarbonate of 1:2:3.4, showed different physical properties than F2 
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and F4 with doubling the amount of citric acid although the ratio of 
the effervescent base within the formula remains constant. The drug 
released from F1and F3 was greater than that from F2 and F4 (table 
4). The difference in the in vitro drug release can be explained to be 
due to the fact that the citric acid may displace the drug from β-
cyclodextrin cavity which led to decrease in its solubility and hence 
it’s amount in the effervescent solution [22, 23]. 
In addition, the results in table 4 showed that all formulas had an 
acceptable pH for pharmaceutical solutions for oral administration 
[24] and effervescent time [4], but they did not release an acceptable 
amount of the drug [25]. This indicates that complexation of the 
drug with β-cyclodextrin only was not sufficient to give the required 
solubility. Therefore, HPMC E5 was added to prepare ternary 
complex.
 
Table 4: Effect of effervescent components on physical properties of granules of carbamazepine/β-cyclodextrin complex 
Parameter F1 F2 F3 F4 
Amount of drug released % 63%±1.73 55.8%±0.782 60%±1.73 47.2%±0.173 
pH 5.6±0 5.1±0.1 5.6±0 5.0±0.1 
Effervescent time (second) 150±0.013 140±0.022 160±0.01 150±0.012 
Results are expressed as mean±SD, n=3 
 
Effect of concentration of effervescent base  
This effect was studied utilizing F5, F6, F7, F8 with the effervescent 
base ratio of (1: 2: 3.4) in different percentage within the formula 
(36%, 48% and 60% and 0%, respectively). 
Slightly higher amount of drug was released from effervescent 
granules (F5, F6, and F7) than dispersible granules (F8) as shown in 
table 5. This indicates that the effervescent base had a role in 
enhancing the solubility of the drug. This result was in agreement 
with that obtained by Om M. Bagade et al. [26]. Same results were 
obtained with an effervescent and dispersible granules (F9 and F10) 
containing 100 mg drug (table 6). 
Effect of concentration of superdisintegrant 
Formulas F1 and F2 with a greater concentration of croscarmellose 
sodium (3%) gave higher in vitro drug release than the 
corresponding formulas of less concentration F3 and F4 (1.5%) as 
shown in table 4. This was because the higher percentage of porous 
particle that enabled them to rapidly absorbed liquid into the 
formula by capillary action and generated rapid volume expansion 
and hydrostatic pressure that resulted in granular disintegration 
leading to increasing the in vitro drug release [16]. Therefore 
croscarmellose sodium in a concentration of 3% was used for the 
preparation of other formulas. 
Determination of flow properties of granules 
The flow properties for those formulas which release an acceptable 
amount of drug are shown in table 7. The values for angle of repose 
were found in the range of 12.09 to 14.3. Carr’s (Compressibility) 
index of the prepared blends falls in the range of 9.19–12.87%. The 
Hausner’s ratio falls in the range of 1.10–1.147% which indicated 
excellent flow properties of all the prepared granules [1]. 
 
Table 5: Effect of concentration of effervescent base of effervescent and dispersible granules of carbamazepine/β-cyclodextrin/HPMC E5 complex 
Parameter F5 F6 F7 F8* 
Amount of drug released % 96.4%±0.173 97.4%±0.173 97.5%±0.264 95.6%±0.264 
pH 5.6±0.1 5.5±0.1 5.6±0 5.7±0.1 
Effervescent time (second) 130±0.021 145±0.02 175±0.01 No effervescence 
Results are expressed as mean±SD, n=3 
 
Table 6: Effect of concentration of effervescent base of effervescent and dispersible granules of carbamazepine/β-cyclodextrin/HPMCE5 
complex equivalent to 100 mg carbamazepine 
Parameter F9 F10* 
Amount of drug released % 97.4%±0.173 95.8%±0.36 
pH 5.6±0.1  5.7±0.1 
Effervescent time (second) 170±0.01 No effervescence 
Results are expressed as mean±SD, n=3 
 
Table 7: Evaluation of flow properties of granules 










F5 14.3±0.265 0.44±0.0.02 0.505±0.01 12.87±0.05 1.147±0.02 
F6 14.28±0.096 0.448±0.01 0.505±0.03 11.28±0.03 1.127±0.05 
F7 14.3±0.173 0.465±0.02 0.528±0.05 11.93±0.03 1.135±0.07 
F8 12.09±0.108 0.430±0.02 0.489±0.01 12.06±0.03 1.137±0.05 
F9 12.3±0.36 0.458±0.01 0.511±0.03 10.37±0.03 1.116±0.02 
F10 12.09±0.082 0.435±0.02 0.479±0.02 9.19±0.01 1.10±0.02 
Results are expressed as mean±SD, n=3 
 
CONCLUSION 
Effervescent and dispersible granules of carbamazepine with good 
flow properties can be successfully prepared by complexation of the 
drug with β-cyclodextrin and HPMC E5 as ternary complex since this 
complex enhance its solubility. Effervescent granules with 
effervescent base of 1:2:3.4 (citric acid/tartaric acid and sodium 
bicarbonate), respectively in an amount not less than 48%w/w and 
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3% w/w croscarmellose sodium within the formula may be 
considered as a more appropriate formulas regarding the amount of 
drug released within 5 min 
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